Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

After playing ball Wednesday during his first confirmation hearing with the Senate Finance Committee, Robert F. | Sens. Bill ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end ...

U.K.-based CDMO Upperton Pharma Solutions expanded its production footprint with the completion of a new £7 million ($8.1 million) sterile manufacturing facility at its Nottingham campus.

CDMO Rentschler Biopharma is moving out of the cell and gene therapy space and putting more of its chips behind biologics. | The German manufacturer is ending operations at its Stevenage, U.K., site ...

Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...